Nanopatch delivery of a tetravalent recombinant subunit dengue vaccine

Depelsenaire, Alexandra C. I., Watterson, Daniel, Zhang, Jin, Yukiko, Sally, Young, Paul R., Kendall, Mark A. F. and Muller, David A. (2013). Nanopatch delivery of a tetravalent recombinant subunit dengue vaccine. In: Australasian Virology Society Meeting 2013, Queenstown, New Zealand, (). 8-11 December 2013.

Author Depelsenaire, Alexandra C. I.
Watterson, Daniel
Zhang, Jin
Yukiko, Sally
Young, Paul R.
Kendall, Mark A. F.
Muller, David A.
Title of paper Nanopatch delivery of a tetravalent recombinant subunit dengue vaccine
Conference name Australasian Virology Society Meeting 2013
Conference location Queenstown, New Zealand
Conference dates 8-11 December 2013
Publication Year 2013
Sub-type Oral presentation
Open Access Status
Language eng
Formatted Abstract/Summary
Dengue is the most significant disease causing arbovirus infection in the world. Indeed the World Health Organisation has listed dengue vaccine development as a priority area for the last 40 years, with the increasing numbers and size of epidemics in recent years only highlighting the importance of vaccine availability. In addition, the increasing geographic range of dengue transmission has resulted in approximately half of the world’s population living in dengue endemic regions. Currently there are estimated to be 390 million dengue infections annually leading to 25,000 – 30,000 deaths. Dengue virus is transmitted by the bite of an infected female Aedes aegypti mosquitoand may result in anything from an asymptomatic infection through to a range of clinical manifestations, including a self-limiting febrile illness dengue fever though to the more severe forms of disease, including dengue haemorrhagic fever and dengue shock syndrome. The envelope (E) protein contains the majority of antibody neutralizing epitopes present on the virus making it an ideal candidate for a subunit vaccine approach. Truncated recombinant E proteins (sE) of all 4 serotypes of dengue virus were expressed in a Drosophila culture (S2 cells) system and delivered to BALB/c mice, with or without Quil A as an adjuvant via subcutaneous injection or via Nanopatch delivery (2 immunizations spaced 4 weeks apart). The Nanopatch contains an ultra high density array (21,025/cm2) of short ~100 μm microprojections. The recombinant proteins are dry coated onto the Nanopatch, and have been shown to be stable, removing the need for a cold chain. Using in house designed spring-loaded applicator devices, Nanopatches can be reproducibly used to deliver vaccine directly to the viable epidermis and dermis. These sites in the skin are rich in antigen presenting cells such as Langerhans and dendritic cells. With only10% of the dose used for the subcutaneous immunizations, mice immunized with the recombinant protein coated Nanopatch showed >1000 fold increase in IgG titre and enhanced virus neutralization. 
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ
Additional Notes Session 16 - Viral Control Strategies I

Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Tue, 02 Sep 2014, 13:29:04 EST by Cathy Fouhy on behalf of Aust Institute for Bioengineering & Nanotechnology